Focus: GE HealthCare is a diagnostic imaging and nuclear medicine company with 714 active job openings, operating across medical devices, contrast agents, and radiopharmaceuticals. The company maintains a portfolio spanning X-ray contrast media, nuclear imaging agents, and advanced imaging modalities.
Profile data last refreshed 9h ago · AI intelligence enriched 2mo ago
Hot — 1636 jobs added in 30d
Net +990 (1636 new, 646 removed). Aggressive expansion phase.
Strong career optionality for engineers and commercial professionals seeking growth in diagnostic imaging; weak choice for pharma scientists expecting robust early-stage drug pipelines.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Legacy contrast agent for urinary bladder imaging; approaching loss of exclusivity with limited clinical differentiation.
Help build intelligence for GE HealthCare
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from GE HealthCare's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Established iohexol formulation for X-ray contrast; mature product with approaching patent expiry and generic competition risk.
Kit-based radiopharmaceutical with limited data; approaching loss of exclusivity.
Established nuclear tracer; approaching end of market exclusivity in competitive diagnostic imaging landscape.
High-concentration iohexol formulation; mature product facing LOE and generic pressure.
Radiopharmaceutical kit with approaching loss of exclusivity.
Chelated imaging agent; mature product approaching patent cliff.
Lower-concentration iohexol formulation; LOE approaching with limited growth prospects.
Radiopharmaceutical kit approaching end of market exclusivity.
Very low-concentration iohexol; niche formulation with approaching LOE.
46 discontinued, 14 duplicate formulations not shown
GE HealthCare reportedly in talks to acquire Sofie Biosciences for $1 billion - DOTmed
GE HealthCare reportedly in talks to acquire Sofie Biosciences for $1 billion DOTmed
GE HealthCare in talks to buy radiopharma firm Sofie Biosciences for $1B - Radiology Business
GE HealthCare in talks to buy radiopharma firm Sofie Biosciences for $1B Radiology Business
GE HealthCare Reportedly In Talks To Buy Sofie Biosciences For About $1 Billion - Pulse 2.0
GE HealthCare Reportedly In Talks To Buy Sofie Biosciences For About $1 Billion Pulse 2.0
GE HealthCare reportedly nears $1bn deal for radiopharmaceutical maker Sofie Biosciences - Dealroom
GE HealthCare reportedly nears $1bn deal for radiopharmaceutical maker Sofie Biosciences Dealroom
GE HealthCare mulls $1B imaging chemicals maker deal: Financial Times - Fierce Biotech
GE HealthCare mulls $1B imaging chemicals maker deal: Financial Times Fierce Biotech
GE HealthCare in talks over possible $1 billion deal for Sofie Biosciences, FT reports - Reuters
GE HealthCare in talks over possible $1 billion deal for Sofie Biosciences, FT reports Reuters
Showing 6 of 10 news items
Based on last 4 crawl cycles
Recent peer-reviewed publications with author affiliations at this company
Showing 5 of 10 publications
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo